Abstract:Purpose: The purpose of this study was to assess the efficacy of an iodine-125 (125I) seed strand combined with a metal stent compared with a metal stent for treatment of obstructive jaundice caused by pancreatic ductal adenocarcinoma (PDAC). Methods and materials: A retrospective analysis was carried out of patients who were referred to Shanghai Zhongshan Hospital of Fudan University with a diagnosis of PDAC between January 1, 2010 and January 31, 2019. A total of 110 consecutive patients with obstructive jaundice caused by PDAC were divided into the iodine-125 seed strand combined with a metal stent group (Group A = 48) and the metal stent group (Group B = 62). The primary outcome was stent obstruction-free survival time, and secondary outcomes were overall survival and complications. Results: The median stent obstruction-free survival time was 133.0 (95% confidence interval (CI): 166.093-149.907) days, and the median overall survival was 212.0 (95% CI: 187.183-236.817) days in all patients. Median stent obstruction-free survival time was 175 days (95% CI 103.165-246.835 days) in Group A versus 120 days (95% CI 87.475-152.525 days) in Group B (p = 0.035). A lower Eastern Cooperative Oncology Group (ECOG) score (p = 0. 000) and iodine-125 seed strand combined with metal stent implantation (p = 0.008) were associated with a longer stent obstruction-free survival time. Obstruction length (p = 0.083), ECOG score (p = 0.000), and iodine-125 seeds (p = 0.037) might have potential impact on stent obstruction-free survival time and were included for multivariable analysis using the Cox proportional hazards model. Stent restenosis was observed in 18.8% (9/48) of patients in Group A and 54.8% (34/62) in Group B, respectively. There was no significant difference in median survival between Group A and Group B (p = 0.409). The median survival in Group A was 209 days (95% CI 150.750-267.250) and 202 days (95% CI 190.624-233.376) in Group B. The median survival of patients with a lower ECOG score was better than that of patients with a higher ECOG score (267 days vs 132 days, p = 0.000). The Grade 3 or 4 complications occurred in 4 (8.3%) of the 48 patients in Group A (one case of hemobilia, one case of liver abscess, two cases of choleperitonitis) and in 5 (8.1%) of the 62 patients in Group B (one case of hemobilia, two cases of liver abscess, two cases of choleperitonitis) (p = 0.972). Conclusions: Implantation of an iodine-125 seed strand combined with a metal stent provides longer obstruction-free survival time compared with a metal stent in patients with obstructive jaundice caused by PDAC. It seems reasonable to choose an iodine-125 seed strand combined with a metal stent as a treatment for these patients.

Iodine-125 Seeds Combined with Biliary Stent Placement Versus Stent Placement Alone for Unresectable Malignant Biliary Obstruction: A Meta-Analysis of Randomized Controlled Trials

Biliary stent with or without 125 I seeds for malignant obstructive jaundice : a systematic review and meta-analysis

Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: a multicentre trial.

Analysis of critical complications and their risk factors after biliary stent implantation for malignant biliary obstruction

Biliary stent combined with iodine-125 seed strand implantation in malignant obstructive jaundice

Biliary Self-Expandable Metallic Stent Combined with Iodine-125 Seeds in the Treatment of Malignant Biliary Obstruction (bismuth Type I or II).

Biliary Stent With Or Without I-125 Seeds For Malignant Obstructive Jaundice: A Systematic Review And Meta-Analysis

A Novel Biliary Stent Loaded with 125I Seeds in Patients with Malignant Biliary Obstruction: Preliminary Results Versus a Conventional Biliary Stent

Efficacy and Safety of the Treatment of 125I Seeds Combined with Stent Implantation for Patients with Malignant Obstructive Jaundice: A Meta-Analysis

Biliary Self-Expandable Metallic Stent Combined with Iodine-125 Seeds in the Treatment of Malignant Biliary Obstruction (bismuth Type I or II)

Malignant Obstructive Jaundice Treated by Intraluminal Brachytherapy Combined with Stent Placement or Stent Implantation Alone

[Development of a New Biliary Intraluminal Irradiation Stent and the Primary Results of Clinical Application].

Conventional Stents Versus Stents Loaded with 125iodine Seeds for the Treatment of Unresectable Oesophageal Cancer: a Multicentre, Randomised Phase 3 Trial

Preliminary clinical study of biliary tract irradiation stent for hilar cholangiocarcinoma with malignant obstructive jaundice

An iodine-125 seed strand combined with a metal stent versus a metal stent alone for obstructive jaundice caused by pancreatic ductal adenocarcinoma

I<SUP>125</SUP> irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis

Chemoembolization and stenting combined with iodine-125 seed strands for the treatment of hepatocellular carcinoma with inferior vena cava obstruction.

Iodine-125 Seeds Insertion with Trans-Arterial Chemical Infusion for Advanced Lung Cancer: a Meta-Analysis.

Study of Percutaneous Stent Placement with Iodine-125 Seed Strand for Malignant Biliary Obstruction

Comparative study of portal vein stent and TACE combined therapy with or without endovascular implantation of iodine-125 seeds strand for treating patients with hepatocellular carcinoma and main portal vein tumor thrombus]

Preliminary application of brachytherapy with double-strand 125I seeds and biliary drainage for malignant obstructive jaundice